– A série Five Thinks to Know About – do Canadian Medical Association Journal, traz pontos-chave de diferentes temas médicos, abordando desde o diagnóstico, tratamento e as recomendações especiais sobre uma condição clínica
– Iniciaremos com três importantes temas no campo da Hematologia: Treating iron deficiency, Myelodysplatic syndrome and Direct oral anticoagulants and the bleedings patients
– Acesse o link para o texto completo original, com imagens e comentários
Treating iron deficiency
– Treating iron deficiency begins with addressing the cause
– Oral iron replacement is first-line therapy
– Supplement selection depends on elemental iron dose, tolerability and cost
– Intravenous iron is second-line therapy
– Dosing of intravenous iron depends on the patient´s iron deficit
■ Treating iron deficiency
M P Zeller, M Verhovsek
CMAJ 2017, vol 189 (10): E409
http://www.cmaj.ca/content/187/14/1074
Myelodysplastic syndrome
– Myleodysplastic syndrome is a disease of older adults and is becoming more common
– Myelodysplastic syndrome commonly presents as fatigue
– Myelodysplastic syndrome should be suspected in older patits with macrocytic anemia
– Patients with unexplained severe or progressive cytopenia should be referred to a hematologist
– Active treatment is available and improves outcomes in myelodysplastic syndrome
■ Myelodysplastic syndrome
R A Wells, R Buckstein, J Rezmovitz
CMAJ 2016, vol 188 (10): 751
http://www.cmaj.ca/content/188/10/751
Direct oral anticoagulants and the bleeding patients
– Direct oral anticoagulant agents are now routinely used for the prevention of stroke in nonvalvular atrial fibrillation
– Risk of bleeding with direct oral anticoagulants is lower than with vitamin K antagonists, but varies by site
– Direct oral anticoagulants are characterized by rapid onset of action and short half-live
– Direct oral anticoagulants variably affect standard clot-based assays
– Idarucizumab has recently been approved by the US Food and Drug Adminstration to reverse the activity of dabigatran
■ Direct oral anticoagulants and the bleeding patient
B Wood, M Sholberg, A Ackery
CMAJ 2016, vol 188 (3): 215
http://www.cmaj.ca/content/188/3/215
by Dr Paulo Fernando Leite
■ Cardiologia/Prevenção Cardiovascular
■ Estratificação de Risco Cardiovascular
Av Contorno 8351 – Conj 01
Belo Horizonte/MG/Brasil
Tel: 31 32919216 2917003 3357229
(- consulta particular –)
CRMMG: 7026
Email: pfleite1873@gmail.com
